^
    2ms
    Clinical Validation of an Ultra-Sensitive ctDNA NGS Assay in HR-Positive, HER2-Negative Breast Cancer Patients (SABCS 2024)
    Plasma samples were collected after first-line aromatase inhibitor (AI) therapy and before initiating second-line treatment with Fulvestrant... The PredicineCARE Ultra ctDNA NGS assay showcased a superior ability to detect low tumor fractions and low-frequency mutations in HR-positive, HER2-negative breast cancer patients, significantly outperforming standard liquid biopsy assays. This enhanced sensitivity offers substantial benefits for early identification of treatment resistance and disease progression, potentially allowing for more timely and tailored therapeutic interventions.
    Clinical • Next-generation sequencing • BRCA Biomarker • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • FGFR3 (Fibroblast growth factor receptor 3) • BAIAP2L1 (BAI1 associated protein 2 like 1) • BAIAP2 (BAR/IMD Domain Containing Adaptor Protein 2)
    |
    TP53 mutation • HR positive • HER-2 negative • PIK3CA mutation • ATM mutation • FGFR3-BAIAP2L1 fusion
    |
    PredicineCARE™
    |
    fulvestrant
    5ms
    Ultra-sensitive ctDNA NGS assay enhances genomic profiling for advanced HR-positive, HER2-negative breast cancer on endocrine therapy (ESMO 2024)
    Plasma samples were collected after aromatase inhibitor treatment and before starting Fulvestrant... The ultra-sensitive ctDNA NGS assay outperformed standard liquid biopsy assays in detecting low-frequency mutations and those from samples with low tumor fractions in HR-positive, HER2-negative breast cancer. Its superior detection may help identify patients suitable for targeted therapies like PIK3CA and ESR1 inhibitors, improving early detection of treatment resistance and disease monitoring for more effective personalized treatment strategies.
    BRCA Biomarker • Next-generation sequencing • Circulating tumor DNA • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • FGFR3 (Fibroblast growth factor receptor 3) • BAIAP2L1 (BAI1 associated protein 2 like 1) • BAIAP2 (BAR/IMD Domain Containing Adaptor Protein 2)
    |
    TP53 mutation • HR positive • HER-2 negative • PIK3CA mutation • FGFR3 fusion • FGFR3-BAIAP2L1 fusion • PTEN mutation + HR positive
    |
    PredicineCARE™
    |
    fulvestrant
    over2years
    Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer. (PubMed, BMC Cancer)
    We demonstrate that increased expression of pERBB3 is a key mechanism of adaptive resistance to FGFR inhibitors in FGFR3-fusion driven bladder cancers, and that this also occurs rapidly following FGFR inhibitor treatment. Our findings demonstrate that resistance can be overcome by combination treatment with a pan-ERBB inhibitor and suggest that upfront combination treatment with FGFR and pan-ERBB inhibitors warrants further investigation for FGFR3-fusion harbouring bladder cancers.
    Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • TACC3 (Transforming acidic coiled-coil containing protein 3) • BAIAP2L1 (BAI1 associated protein 2 like 1)
    |
    FGFR3-TACC3 fusion • FGFR3 fusion • FGFR3-BAIAP2L1 fusion
    |
    Mekinist (trametinib) • Balversa (erdafitinib) • Truseltiq (infigratinib) • Lytgobi (futibatinib) • sapitinib (AZD8931)
    over2years
    Clinicopathological characterization, FGFR alteration prevalence, and outcomes of locally advanced or metastatic urothelial cancer in Latin America (LACOG 1518). (ASCO 2022)
    Gemcitabine-platinum combinations were the backbone of choice in 93.7% of pts receiving combined chemotherapy. Pembrolizumab and atezolizumab were the chosen first-line agents for 10.3% and 4% of the treated pts, respectively... The prevalence of FGFR alterations in advanced UC in Latin America is similar to those described in other regions. Our data suggest limited access to FGFR inhibitors for the treatment of advanced UC in Latin America.
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • TACC3 (Transforming acidic coiled-coil containing protein 3) • BICC1 (BicC Family RNA Binding Protein 1) • BAIAP2L1 (BAI1 associated protein 2 like 1) • CASP7 (Caspase 7)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 G370C • FGFR3 R248C • FGFR3-BAIAP2L1 fusion
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • gemcitabine
    almost3years
    Prognostic impact of fibroblast growth factor receptor (FGFR) genomic alterations and outcomes in patients with metastatic urothelial. (ASCO-GU 2022)
    Despite a better response to first line treatment, overall FGFR GA showed to be an independent risk factor in mUC. Thus, this determination should be included in new prognostic models. Univariable and multivariable analysis for overall survival in the first line treatment setting for mUC.
    Clinical
    |
    FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • BICC1 (BicC Family RNA Binding Protein 1) • BAIAP2L1 (BAI1 associated protein 2 like 1) • CASP7 (Caspase 7)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 G370C • FGFR3 R248C • FGFR3-BAIAP2L1 fusion • FGFR wild-type
    |
    FoundationOne® CDx • therascreen® FGFR RGQ RT-PCR Kit